According to Yigoo, Hrain Biotechnology Co., Ltd. (Hrain), a cell therapy enterprise in Shanghai, announced that it had completed B round financing of 200 million yuan, led by SCGC and followed by Yangming Kangyi, Jun Chen Da Capital, Zhang Long Hai Fa, Shanghai Yongrun, Zeyu Capital and Qianhai Capital. The funds will be used for the registration of clinical trials, the industrialization of Hrain’s CAR-T products, and the foundation for IPO plans.
Hrain Biotechnology Co., Ltd. is located in Shanghai Zhangjiang Hi-Tech Park. Adhering to the idea of relieving patients from diseases, Hrain focuses on R&D and the application of tumor immunotherapy technologies and the transformation of the latest foreign tumor immunotherapy technologies.
Hrain has an R&D pattern of one center and multiple highlights, with CAR-T technology as the center while CAR-NK, new DC vaccines, iNKT and other technologies being promoted in parallel. It has several CAR-T clinical trials registered on ClinicalTrials.gov, an authoritative platform for exchanges of clinical experience in America. Its clinical trial now could be carried out in the United States, Europe, and the Middle East and will extend its reach to more countries.
At present, there are three clinical trial approvals for CAR-T products targeted at CD19 and BCMA, which can be used for the treatment of lymphoma, leukemia, multiple myeloma, etc., making Hrain hold the most CAR-T approvals for blood tumor in China. Besides, Hrain started the construction of CAR-T GMP preparation center of about 11,000 square meters in Shanghai Zhangjiang Jinshan Biological Medicine Base for large-scale industrial production in 2018.
SCGC is a limited venture capital company established by Shenzhen Government in 1999. SCGC has a registered capital of 5.42 billion RMB. It primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc.
By the end of August 2019, SCGC has 1028 portfolio companies with investments of totaling 45.8 billion RMB.